Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FC-1 is a small molecule proteolysis-targeting chimera (PROTAC) designed to induce the selective degradation of focal adhesion kinase (FAK). Developed by researchers at Tsinghua University, FC-1 consists of a FAK-binding moiety linked to a Cereblon (CRBN) E3 ubiquitin ligase ligand. This bifunctional molecule brings FAK into close proximity with the E3 ligase complex, triggering the polyubiquitination and subsequent proteasomal degradation of the FAK protein. FAK is a non-receptor tyrosine kinase that is frequently overexpressed in various cancers, where it plays a critical role in tumor cell signaling, survival, and metastasis through both its kinase activity and its scaffolding functions. By eliminating the entire protein, FC-1 potentially offers a more comprehensive therapeutic approach than traditional kinase inhibitors, which only block enzymatic activity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on FC-1.